In the past few weeks Hikma Pharmaceuticals’ share sharply fell but the stock is presently coming back near a significant support area.

The current valuation shows a +12% potential to reach the consensus average target price. Moreover, some investment banks recently rose their target prices. Sales should rise around 4%.

Hikma Pharmaceuticals is presently in an oversold situation, as technical indicators show. The stock is currently on contact with its rising trend line. Moreover, the closeness of the significant GBp 1982 weekly support should prevent the share from any further correction. The area formed by those 2 technical aggregates could act as a basis for a forthcoming acceleration.
Consequently, investors may open a long position at current prices and target the GBp 2245 pivot point as a first goal. A stop loss order should set at GBp 1920.